G-1 Appeal Activity in the Public Assistance Programs, February 2002

Monthly report from the Iowa Department of Human Services

G-1 Appeal Activity in the Public Assistance Programs, December 2001

Monthly report from the Iowa Department of Human Services

G-1A Appeal Activity in the Public Assistance Programs, July 2002-June 2003

Yearly report from the Iowa Department of Human Services

A-1A Supplemental Security Income Program, June 2004

Monthly report about supplemental income produced by the Iowa Department of Human Services.

A-1A Supplemental Security Income Program, July 2004

Monthly report about supplemental income produced by the Iowa Department of Human Services.

A-1A Supplemental Security Income Program, August 2004

Monthly report about supplemental income produced by the Iowa Department of Human Services.

G-1 Appeal Activity in the Public Assistance Programs, August 2004

Monthly report from the Department of Human Services on the appeal activity in the public assistance programs.

Iowa Water Pollution Control Works and Drinking Water Facilities Financing Programs (Joint Programs of the Iowa Finance Authority and the Iowa Department of Natural Resources), Independent Auditor's Reports Financial Statements and Supplemental Information Schedule of Findings, June 30, 2003

State Agency Audit Report

G-1 Appeal Activity in the Public Assistance Programs, September, 2004

APPEAL ACTIVITY IN THE PUBLIC ASSISTANCE PROGRAMS

A-1A Supplemental Security Income Program, September 2004

Supplemental Security Income Program

A-1A Supplemental Security Income Program, October 2004

Supplemental Security Income Program

G-1 Appeal Activity In The Public Assistance Programs, October 2004

G-1 Appeal Activity In The Public Assistance Programs

G-1, Appeal Activity In The Public Assistance Programs, November 2004

Appeal Activity In The Public Assistance Programs

A-1A Supplemental Security Income Program, November 2004

Supplemental Security Income Program

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Purpose: Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and promising activity in recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma. Patients and Methods: Patients (age >= 18 to >= 70 years) were treated with cilengitide (500 mg) administered twice weekly intravenously in addition to standard radiotherapy with concomitant and adjuvant temozolomide. Treatment was continued until disease progression or for up to 35 weeks. The primary end point was progression-free survival (PFS) at 6 months. Results: Fifty-two patients ( median age, 57 years; 62% male) were included. Six- and 12-month PFS rates were 69% (95% CI, 54% to 80%) and 33% ( 95% CI, 21% to 46%). Median PFS was 8 months ( 95% CI, 6.0 to 10.7 months). Twelve- and 24-month overall survival ( OS) rates were 68% ( 95% CI, 53% to 79%) and 35% ( 95% CI, 22% to 48%). Median OS was 16.1 months ( 95% CI, 13.1 to 23.2 months). PFS and OS were longer in patients with tumors with O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months). The combination of cilengitide with temozolomide and radiotherapy was well tolerated, with no additional toxicity. No pharmacokinetic interactions between temozolomide and cilengitide were identified. Conclusion: Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation. J Clin Oncol 28:2712-2718. (C) 2010 by American Society of Clinical Oncology